The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

Inclusion Criteria: * Patients diagnosed with malignant tumors who can receive 3-day chemotherapy regimens defined by the protocol; * The two-cycle sequential chemotherapy must be the same in drugs, dosage, sequence and routes of administration; * Patients are prohibited from any other chemotherapy drugs during the study, as well as other antiemesis, sedative and psychotropic drugs within 5 days after chemotherapy; * Life expectancy ≥ 3 months; * Adequate hematologic function; * Adequate hepatic function; * Adequate renal function; * At least 2 weeks away from the last chemotherapy; * Patients signed written informed consent. Exclusion Criteria: * Pregnant or lactating women; * History of anticipatory vomiting; * Radiation therapy on the abdomen or pelvis within one week prior to study entry; * Concomitant use of other drugs which may affect the antiemetic effects (such as omeprazole, amifostine, etc.); * Patients with gastrointestinal obstruction; * Patients with severe heart disease, liver or renal disease, or metabolism disorders; * Patients with epilepsy or using sedative or psychotropic drugs; * Patients with diabetes or with contraindication for corticosteroids; * Patients who received antiemetic drugs or experienced nausea or vomiting within 24 hours prior to study entry; * Patients with brain metastasis or intracranial hypertension; * Hypersensitivity to 5-HT3 receptor antagonist; * Patients with active infection; * Other conditions that the investigator considered as unsuitable for chemotherapy; * Subjects participating in other clinical trials.